APA (7th ed.) Citation

Al‐Kassou, B., Veulemans, V., Shamekhi, J., Maier, O., Piayda, K., Zeus, T., . . . Sedaghat, A. (2023). Optimal protamine‐to‐heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR—A multicenter experience. Clinical Cardiology, 46(1), 67-75. https://doi.org/10.1002/clc.23936

Chicago Style (17th ed.) Citation

Al‐Kassou, Baravan, et al. "Optimal Protamine‐to‐heparin Dosing Ratio for the Prevention of Bleeding Complications in Patients Undergoing TAVR—A Multicenter Experience." Clinical Cardiology 46, no. 1 (2023): 67-75. https://doi.org/10.1002/clc.23936.

MLA (9th ed.) Citation

Al‐Kassou, Baravan, et al. "Optimal Protamine‐to‐heparin Dosing Ratio for the Prevention of Bleeding Complications in Patients Undergoing TAVR—A Multicenter Experience." Clinical Cardiology, vol. 46, no. 1, 2023, pp. 67-75, https://doi.org/10.1002/clc.23936.